In anti-MDA5 antibody-negative ILD, longitudinal HRCT imaging to track the progression of traction bronchiectasis and bronchiolectasis, new GGO with traction bronchiectasis, fine reticulation, and coarsened reticular abnormalities may indicate the timing of antifibrotic therapy to effectively manage fibrosis progression. Here, IFIH1 is linked to interstitial lung disease.